BTG3 and colorectal cancer: Comparison between ICI- and ICI+ groups revealed significant ANA increases in colorectal cancer (32.3%, P = 0.049), hepatocellular carcinoma (52.6%, P = 0.036), and renal cell carcinoma (53.8%, P = 0.047) compared with the ICI- group (Table 5).